Cannabidiol (CBD) Medicinal Products Reaching New Level of Acceptance in the Healthcare Industry

Palm Beach, FL – (October 10, 2018) – The medicinal cannabis industry may appear to be lagging behind the legal niches of CBD and recreational cannabis, but the reality is, leaders in the space are still generating strong revenues behind increased momentum regarding how cannabis is viewed as a viable medical treatment. More researchers and medical professionals are interested in cannabis, and the need for education is pronounced. Efforts to educate patients are also gaining steam, especially as more people turn to medical marijuana for assistance in managing the symptoms of many different conditions.  In order to capitalize on this momentum, companies are releasing new products with the hope of capturing new and emerging markets. The medicinal cannabis market has been steadily growing over the past few years and it is expected to grow to $55.8 billion by 2025, according to Grand View Research. Much of this growth will be due to momentum building on itself, but educational efforts, product advancements and a reduction in alcohol’s popularity will also play roles in the growth.  Active cannabis companies in the markets this week include Empower Clinics Inc. (CSE:EPW) (OTC:EPWCF), GW Pharmaceuticals plc. (NASDAQ:GWPH), MedMen Enterprises Inc. (OTC:MMNFF) (CSE:MMEN), Aphria Inc. (OTC:APHQF) (TSX:APH), Canopy Growth Corporation (NYSE:CGC) (TSX:WEED).


Empower Clinics Inc. (CSE:EPW) (OTCPK:EPWCF) BREAKING NEWS:  Empower Clinics, a leading owner and operator of medical cannabis and wellness clinics in the US, today announced a comprehensive agreement with Titration Technologies, LLC, an innovator in cannabis product development, to manufacture, package, and fulfill Empower’s “Sollievo” CBD medical cannabis products throughout North America.


Empower’s “Sollievo” (Italian for “relief”) products specifically target the most common qualifying medical conditions, involving pain, sleep, stress, and digestion.  The products, available as tinctures or topical creams, are non-THC CBD, meaning that they are non-psychotropic: they do not directly affect mood, perception, or consciousness.


As part of the agreement, Titration will produce Empower-formulated CBD medical cannabis products, which Empower will sell under its “Sollievo” product brand on Empower’s Website, at Empower clinics, as well as select third-party wellness clinics throughout the US and Canada.  The products will be available at in the coming weeks.


“This agreement enables patients in all 50 states and Canada to access Empower’s CBD products, which is an important milestone as we continue to expand our business and service areas,” said Craig Snyder, Empower CEO.  “As we grow our footprint of medical cannabis and wellness clinics, product sales are an important market channel and revenue stream for us.  We are excited to be working with a proven leader like Titration and their team of respected plant scientists.”


Under the agreement, Titration will provide product manufacturing, packaging, warehousing, and fulfillment for Empower.   “Empower has been rapidly building its business and we are looking forward to working with them in providing a superior line of CBD products,” said Jason Sonchik, Titration Director of Quality Control. Read this and more news for Empower Clinics at   


Other recent developments in the cannabis industry include:


GW Pharmaceuticals plc. (NASDAQ:GWPH) closed Tuesday up slighly at $146.20 with a volume north of 430,000 by the market close. Last week, the company announced the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses). Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, J.P. Morgan and Cowen and Company, LLC acted as joint book-running managers for the offering. The ADSs described above were offered by GW pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission (“SEC”) that became automatically effective on April 17, 2017.


MedMen Enterprises Inc. (OTCQB:MMNFF) (CSE:MMEN.CN) recently announced it launched a comprehensive suite of new cannabis products under the brand [statemade] during the opening of its second store in Las Vegas, MedMen Paradise. [statemade] is aimed at the modern cannabis consumer and leverages MedMen’s retail brand and reach. The products launch exclusively at MedMen Paradise in Nevada and the Company plans to manufacture and sell [statemade] in all markets where it is licensed to operate including Arizona, California, Florida and New York, as well as other future markets. “We’ve built one of the most popular and trusted retail brands in cannabis today,” said MedMen co-founder and President Andrew Modlin. “And if there is one thing we’ve learned from serving hundreds of thousands of customers at our stores is that the modern cannabis consumer wants high-quality products in a variety of forms. They want to enhance their well-being and enjoy new experiences with the assurance that what they are putting in their bodies has been fully tested and safe. [statemade] offers one of the most comprehensive suites of products available in the market today using MedMen’s class leading cultivation and manufacturing expertise.”


Aphria Inc. (OTCQB:APHQF) (TSX:APH.TO) recently unveiled its comprehensive portfolio of adult-use brands that will be available for sale in the adult-use market. Backed by more than a year and a half of extensive qualitative and quantitative research, including focus groups and influencer consultations, the Company has developed a portfolio of brands designed to meet the needs of specific consumer segments. The brands feature a range of price points and offer a variety of product formats and consumption options tailored to consumer preferences. “When we embarked on our journey to develop our adult-use brands, we were committed to truly understanding what cannabis users would look like after legalization,” said Megan McCrae , Vice President of Marketing at Aphria. “We undertook extensive research to understand each segment of the market and build a broad portfolio of brands that would speak to each of those varied and diverse groups. This consumer-centric approach is the cornerstone of every one of our thoughtfully-created brands and will continue to drive our ongoing product development and brand positioning.”


Canopy Growth Corporation (NYSE:CGC) (TSX:WEED.TO) recently announced on Tuesday that it has completed a legal transfer of cannabis products to a research partner in the United States. To the Company’s knowledge, this transfer is the first export of legal cannabis products from Canada to the United States pursuant to an import permit issued by the federal United States Drug Enforcement Administration (DEA). The shipment was completed for the sole purpose of supporting medical research and development. Currently, sources of federally regulated cannabis in the United States are limited in scope and genetic diversity. Canopy Growth believes that it can add value to the market and enable the development of rigorous testing standards for products, while advancing the understanding of the risks and benefits of medical cannabis. The advancement of this research stands to serve Americans, Canadians and those around the world who may benefit from legal, approved cannabis based medical treatments.


DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates and, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press releases issued by Empower Clinics Inc. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: – +1(561)325-8757